ABSTRACT
Objective To observe the clinical efficacy and safety of local injection of botulinum toxin type A (BTX-A) in the treatment of Migraine.Methods 31 patients in the treatment group were injected BTX-A 25 U at 10 positions at the muscles.30 patients in the control group were given 2％ lidocaine 1 ml plus prednisolone acetate 1 ml at the same muscle sites as in the treatment group.Days,frequency,and intensity of headache were evaluated by visual analogue scale (VAS),migraine disability was evaluated by migraine disability assessment guestionnaire (MIDAS),and adverse reactions were assessed on 1 month before the treatment and 1st,2st,3st months after the treatment.Results The therapeutic effect between the treatment and control groups was significantly different in terms of days,frequency,and intensity of headache and migraine disability.Compared with preinjection,days and frequency of headache and migraine disability were decreased significantly after injection in treatment group,lasting more than 2 months.No patients in two groups reported any serious treatment-related adverse event.Conclusions Botulinum toxin type A in the treatment of Migraine is effective and relative safe,and can decrease migraine disability.